PRLD Strangle Strategy
PRLD (Prelude Therapeutics Incorporated), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
PRLD (Prelude Therapeutics Incorporated) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $259.7M, a beta of 1.10 versus the broader market, a 52-week range of 0.75-5.54, average daily share volume of 394K, a public-listing history dating back to 2020, approximately 131 full-time employees. These structural characteristics shape how PRLD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.10 places PRLD roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on PRLD?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current PRLD snapshot
As of May 14, 2026, spot at $4.48, ATM IV 143.00%, IV rank 28.66%, expected move 41.00%. The strangle on PRLD below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on PRLD specifically: PRLD IV at 143.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a PRLD strangle, with a market-implied 1-standard-deviation move of approximately 41.00% (roughly $1.84 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PRLD expiries trade a higher absolute premium for lower per-day decay. Position sizing on PRLD should anchor to the underlying notional of $4.48 per share and to the trader's directional view on PRLD stock.
PRLD strangle setup
The PRLD strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PRLD near $4.48, the first option leg uses a $4.70 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PRLD chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PRLD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.70 | N/A |
| Buy 1 | Put | $4.26 | N/A |
PRLD strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
PRLD strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on PRLD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on PRLD
Strangles on PRLD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PRLD chain.
PRLD thesis for this strangle
The market-implied 1-standard-deviation range for PRLD extends from approximately $2.64 on the downside to $6.32 on the upside. A PRLD long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current PRLD IV rank near 28.66% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PRLD at 143.00%. As a Healthcare name, PRLD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PRLD-specific events.
PRLD strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PRLD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PRLD alongside the broader basket even when PRLD-specific fundamentals are unchanged. Always rebuild the position from current PRLD chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on PRLD?
- A strangle on PRLD is the strangle strategy applied to PRLD (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With PRLD stock trading near $4.48, the strikes shown on this page are snapped to the nearest listed PRLD chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PRLD strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PRLD strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 143.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PRLD strangle?
- The breakeven for the PRLD strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PRLD market-implied 1-standard-deviation expected move is approximately 41.00%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on PRLD?
- Strangles on PRLD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PRLD chain.
- How does current PRLD implied volatility affect this strangle?
- PRLD ATM IV is at 143.00% with IV rank near 28.66%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.